. 2022 May 30;36(6):633–647. doi: 10.1007/s40263-022-00926-0

Table 1.

Dosing of LXB and other anticataplectics during OLOTTP

Group	Treatment at study entry	Treatment during OLOTTP	OLOTTP
Group	Treatment at study entry	Treatment during OLOTTP	Weeks 1–2	Weeks 3–10	Weeks 11–12
A	SXB only	LXB	Same dose as for prior SXB	Titrate as needed	Steady optimal dose; adjust dose only if necessary
B	SXB + other anticataplectics	LXB	Same dose as for prior SXB	Titrate as needed	Steady optimal dose; adjust dose only if necessary
B	SXB + other anticataplectics	Other anticataplectic	Same dose as before	Taper and withdraw	N/A^a
C	Other anticataplectics	LXB	4.5 g/night (split across 2 doses), titrated as needed	Titrate as needed	Steady optimal dose; adjust dose only if necessary
C	Other anticataplectics	Other anticataplectic	Same dose as before	Taper and withdraw	N/A^a
D	Anticataplectic naive	LXB	4.5 g/night (split across 2 doses), titrated as needed	Titrate as needed	Steady optimal dose; adjust dose only if necessary

LXB lower-sodium oxybate, N/A not applicable, OLOTTP open-label optimized treatment and titration period, SXB sodium oxybate

^aAdditional time for tapering and withdrawal of prior anticataplectics was permitted if needed